newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

  • Bezuclastinib achieved significant improvements across all symptom domains in the SUMMIT trial, including 11 individual symptoms plus the most severe baseline symptom.
  • Reducing objective disease measures like serum tryptase correlated with improved symptom severity in NonAdvSM patients, marking the first time this has been shown.
  • New 48-week data demonstrate continued deepening of symptomatic improvement over time.
  • The drug showed a favorable safety & tolerability profile supporting chronic use, with most treatment-emergent adverse events being low grade.
  • Bezuclastinib received Breakthrough Therapy Designation in October 2025, with a New Drug Application submission planned for December 2025.
  • In the Part 2 SUMMIT trial, 118 patients received bezuclastinib while 60 received placebo, with 65.4% of bezuclastinib patients achieving ≥30% reduction in Total Symptom Score (TSS) at 24 weeks versus 38.6% for placebo.
  • At 48 weeks, the mean TSS change for bezuclastinib patients was -32.0% (-54%), with 86.2% achieving ≥30% reduction in TSS.
  • 87.4% of bezuclastinib patients achieved ≥50% reduction in serum tryptase, 75.6% reduced bone marrow mast cells, and 85.7% reduced KIT D816V variant allele frequency at week 24.
  • Subgroups including Smoldering Systemic Mastocytosis patients & those previously treated with avapritinib showed consistent responses in symptom & objective disease measures.
  • Common adverse events included hair color change (69.5%), altered taste (23.7%), nausea (22.0%), & ALT/AST elevations (22.0%), with discontinuations due to treatment-related AEs occurring in 5.9% of patients.
  • Cogent will host an investor conference call & webcast on Monday, December 8, at 8:00 a.m. ET to discuss these results.